Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Trial Timeline
Dec 11, 2023 → Feb 12, 2029
NCT ID
NCT06065748About Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist is a phase 3 stage product being developed by Roche for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06065748. Target conditions include Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06065748 | Phase 3 | Recruiting |
Competing Products
20 competing products in Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer